Ipamorelin

At a glance

Overview

Ipamorelin was developed as a relatively selective growth hormone secretagogue within the GHRP family. Early animal work found less stimulation of some other pituitary hormones than comparator peptides, but that does not establish a universally side-effect-free human profile. Healthy-volunteer studies examined intravenous pharmacokinetics and GH release. A later trial investigated postoperative ileus because ghrelin signaling also affects gastrointestinal motility. None of these programs establishes a routine wellness indication or validates arbitrary subcutaneous combinations sold by clinics. FDA has specifically discussed the limited safety information for compounded ipamorelin and the uncertainty of extrapolating findings across routes of administration.

Supporting sources [1] [2] [3] [4]

How it works

Ipamorelin activates the growth hormone secretagogue receptor, also called the ghrelin receptor, in the hypothalamic–pituitary system and other tissues. This can trigger GH secretion and affect gastrointestinal motility. It acts through a different receptor from GHRH analogs such as sermorelin. Early experiments suggested relative endocrine selectivity, but receptor selectivity and clinical safety are different questions, particularly when treatment is repeated or combined with other agents.

Supporting sources [1] [2] [3] [4]

What the clinical studies support

A healthy-volunteer study demonstrated GH release after intravenous ipamorelin. In a randomized postoperative study, the key endpoint was time to tolerance of a standardized solid meal; the difference from placebo was not statistically significant. The population and outcome also differ substantially from the muscle-building claims commonly made online.

Supporting sources [1] [2]

How should safety reports be interpreted?

FDA notes serious adverse events, including deaths, in the intravenous gastrointestinal-motility literature and insufficient information for certain other injection routes. These events occurred in a postoperative population and do not by themselves prove drug causation. They do prevent a confident claim that ipamorelin has a settled, benign human safety profile.

Supporting sources [2] [3]

Investigational status

Ipamorelin is not an FDA-approved medicine. FDA also raises concerns about immune reactions, aggregation, unnatural amino acids, and impurity characterization in compounded preparations. A compound’s ability to release GH is not a regulatory authorization for treating age-related symptoms, obesity, or athletic injuries.

Supporting sources [3]

Does selectivity mean no cortisol or metabolic effects?

The original selectivity findings came largely from experimental systems and animals. They cannot guarantee the endocrine response in every human or under repeated combined treatment. Demonstrating a smaller effect on one hormone does not answer questions about glucose regulation, fluid retention, product purity, or long-term outcomes.

Supporting sources [4] [3]